Raltegravir (MK-0518)

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh, Merck Sharp & Dohme LLC

Conditions

HIV InfectionHIV Infections

Phase 2

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

CompletedNCT00515827

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-11-30End: 2008-11-30Updated: 2021-11-04

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

TerminatedNCT02116660

Merck Sharp & Dohme LLCHIV Infections

Start: 2014-09-03End: 2017-07-10Updated: 2019-04-08

Unknown Phase

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

CompletedNCT00618371

University of PittsburghHIV Infection

Start: 2007-10-31End: 2009-03-31Updated: 2017-02-01

Related Papers

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

2010-08-10244 citations

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

2010-03-01189 citations